Publications by authors named "Jian-suo Zhou"
[Sensitization Spectrum of 16 362 Patients with Allergic Diseases in Peking University Third Hospital].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2022
Objective To retrospectively analyze the sensitization spectrum of 16 362 patients with allergic diseases treated in the Peking University Third Hospital and provide reference for the prevention and treatment of allergic diseases.Methods A total of 16 362 patients with allergic diseases treated in the Peking University Third Hospital from January 2009 to September 2021 were selected.The serum levels of total IgE and antigen-specific IgE(sIgE)were determined.
View Article and Find Full Text PDFStudy Question: What are the roles of maternal 5,10-methylenetetrahydrofolate reductase () C677T/A1298C combination polymorphisms on the embryological and clinical outcomes of IVF/ICSI?
Summary Answer: Our study reveals for the first time that the oocyte maturation potential gradually decreases with a reduction of maternal MTHFR activity determined by combined C677T/A1298C polymorphisms, while embryo quality was worse in women with intermediate MTHFR activity.
What Is Known Already: Although many previous studies have explored the association between polymorphisms and IVF/ICSI outcomes, the results remain contradictory due to inadequate samples, no adjustment for potential confounders and/or the study of C677T and A1298C separately. Few studies have systematically investigated the exact role of MTHFR activity determined by combined C677T/A1298C polymorphisms on the embryological and clinical outcomes of IVF/ICSI.
Background: Matrix metalloproteinase 3 (MMP3) is known as an inflammatory factor; however, the effectiveness of MMP3 for diagnosis of pneumonia and predicting outcomes is unclear. We evaluated the diagnostic and prognostic value of serum MMP3 in patients with pneumonia.
Methods: One hundred and eighty-five patients with pneumonia and 52 healthy controls were enrolled.
[Combination of AD5-10 and epirubicin in treating rheumatoid arthritis].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
August 2011
Article Synopsis
- The study aims to explore how the combination of anti-death receptor 5-10 (AD5-10) and the drug epirubicin can treat rheumatoid arthritis (RA).
- Researchers assessed the viability of synoviocytes from RA patients and analyzed specific apoptosis-related proteins using Western blot techniques.
- Results indicated that epirubicin enhances the pro-apoptotic effects of AD5-10 on synoviocytes by altering levels of apoptosis regulators like p53, p21, and Bcl-2.